Physicians have traditionally been gatekeepers to prescription medications. Their assessment of patients’ risk-benefit profile, for example, dictates their access to these medications—sometimes controversially, as in the current opioid epidemic. More recently, escalating prices, formulary restrictions, and other clinician-prescribers have reshaped physicians’ roles. This month’s issue explores these changes and strategies for improving access to medications patients need.
Since the 1960s, drug names have been products of complex, multiparty negotiations in which interests of patients, pharmaceutical firms, clinicians, and US and international regulators must be balanced.
AMA J Ethics. 2019;21(8):E686-696. doi:
How do we determine what a fair price for a life-saving prescription medication should be? This month, we discuss what is means for a price to be “fair” and explore the current legal and economic landscape of prescription drug pricing in the US.
Should a law’s intent or practical applications be regarded as more important?
Should a patient with substance use disorder receive Medicaid-funded therapy for hepatitis C?